BOD Australia Ltd
ASX:BOD
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.024
0.024
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
|
BOD Australia Ltd
ASX:BOD
|
4.3m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
213.9B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -1 894 850% |
| 30th Percentile | -130.1% |
| Median | 1.6% |
| 70th Percentile | 10.8% |
| Max | 145 596.9% |
Other Profitability Ratios
BOD Australia Ltd
Glance View
Bod Australia Ltd. operates as a developer, manufacturer, distributor, importer, exporter and marketer of skincare, beauty, and health industries for the natural segment of the market. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-10-27. The firm is engaged in the development and manufacture of cannabidiol (CBD) and hemp products for consumer markets in Australia and United Kingdom, as well as the development, manufacture and distribution of therapeutics medicinal cannabis products. The firm operates through three segments: medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for BOD Australia Ltd is 11.6%, which is above its 3-year median of -125.1%.
Over the last 3 years, BOD Australia Ltd’s Operating Margin has increased from -109.7% to 11.6%. During this period, it reached a low of -269.1% on Dec 31, 2023 and a high of 11.6% on Jul 30, 2025.